2026年上半年业绩回顾:药明合联(2268.HK)业绩超预期
高盛·2026-08-26 14:45
权益研究 2026年8月25日 | 1 7:30港區時間 | GS预测 | | | | | | --- | --- | --- | --- | --- | | | 12/25 | 12/26E | 12/27E | 12/28E | | Revenue (Rmb mn) New | 5,944.2 | 8,134.2 | 10,778.7 | 13,702.1 | | Revenue (Rmb mn) Old | 5,944.2 | 7,925.3 | 10,425.9 | 13,189.7 | | EBITDA (Rmb mn) | 1,809.6 | 2,482.1 | 3,326.6 | 4,342.8 | | EPS (Rmb) New | 1.22 | 1.45 | 2.18 | 2.84 | | EPS (Rmb) Old | 1.22 | 1.53 | 2.12 | 2.80 | | P/E (X) | 38.1 | 41.4 | 27.5 | 21.1 | | P/B (X) | 5.4 | 5.9 | 4.8 | 3.9 | | Dividend yield (%) | 0.0 | 0.0 ...